Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA study

被引:8
|
作者
Schoendorf, Thomas [1 ,2 ,3 ]
Luebben, Georg [4 ]
Karagiannis, Efstrathios [4 ]
Erdmann, Erland [2 ]
Forst, Thomas [1 ]
Pfuetzner, Andreas [1 ,3 ]
机构
[1] Inst Clin Res & Dev, Mainz, Germany
[2] Univ Cologne, Med Ctr, Cologne, Germany
[3] Univ Appl Sci, Dept Appl Nat Sci, Rheinbach, Germany
[4] Takeda Pharma, Aachen, Germany
来源
关键词
cardiodiabetes; cardiovascular risk; biomarker profile; angiodiabetes; IMPAIRED FASTING GLUCOSE; CORONARY-ARTERY-DISEASE; MYOCARDIAL-INFARCTION; NONDIABETIC PATIENTS; INSULIN-RESISTANCE; MELLITUS; HEART; PIOGLITAZONE; SIMVASTATIN; PROINSULIN;
D O I
10.1177/1479164109358241
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Patients with diabetes mellitus and IGT have a high risk for cardiovascular events. It is tempting to speculate that these patients are often first seen by cardiologists. Design: This cross-sectional study investigates the diabetes prevalence in cardiology care units and the correlated metabolic conditions as assessed by several circulating biomarkers. Methods: Patients aged 55 or older with suspected or overt coronary heart disease were eligible for trial participation. Fasting blood samples were drawn from patients to determine HOMA score, glycaemic and lipid profile, and several risk biomarkers. An OGTT was performed in patients without known diabetes. Results: We enrolled 530 patients (181 male, 349 female, mean age, 68 +/- 7 years) in this study from 22 German cardiology centres; 156 patients (29.4%) had known diabetes and OGTT revealed that 184 patients (34.7%) had no diabetes, 106 patients (20.0%) had IGT or IFG and 84 patients (15.9%) were newly diagnosed with diabetes. Increased cardiovascular risk as reflected by increased hsCRP, ICAM and MMP-9 values was observed in diabetes patients. A higher cardiovascular biomarkers risk profile was seen in the IGT/IFG cohort. Conclusions: This study confirms the observation that one third of patients of a cardiologic care unit suffer from impaired glucose regulation. Furthermore, the cardiology patients with previously unknown glucose homeostasis abnormalities had a higher prevalence of macrovacular disease and an impaired biomarker risk profile. This study underlines the importance of joint treatment efforts by cardiologists in concert with diabetologists for treatment of this patient group at high risk for cardiovascular events.
引用
下载
收藏
页码:145 / 150
页数:6
相关论文
共 50 条
  • [1] Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists -: results from the DIASPORA Study
    Schoendorf, T.
    Karagiannis, E.
    Erdmann, E.
    Luebben, G.
    Jenke, B.
    Loebig, M.
    Forst, T.
    Pfuetzner, A.
    DIABETOLOGIA, 2007, 50 : S148 - S148
  • [2] INCREASED PREVALENCE OF CARDIOVASCULAR RISK FACTORS IN NEWLY DIAGNOSED TYPE 2 DIABETES PATIENTS - A RETROSPECTIVE STUDY
    Roman, G.
    Teodorescu, G.
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2021, 17 (03)
  • [3] Cardiovascular disease risk communication for patients with type 2 diabetes: The @RISK Study
    Welschen, L. M. C.
    Bot, S. D. M.
    van der Weijden, T.
    Timmermans, D. R. M.
    Dekker, J. M.
    Nijpels, G.
    DIABETOLOGIA, 2010, 53
  • [4] Cardiovascular disease prevalence in adults with type 2 diabetes in Japan: results from the Japanese centers in the CAPTURE study
    Seino, Hiroaki
    Onishi, Yukiko
    Eguchi, Kosei
    Nishijima, Keiji
    Sato, Toshihiro
    Shirabe, Shinichiro
    DIABETOLOGY INTERNATIONAL, 2023, 14 (02) : 172 - 182
  • [5] Cardiovascular disease prevalence in adults with type 2 diabetes in Japan: results from the Japanese centers in the CAPTURE study
    Hiroaki Seino
    Yukiko Onishi
    Kosei Eguchi
    Keiji Nishijima
    Toshihiro Sato
    Shinichiro Shirabe
    Diabetology International, 2023, 14 : 172 - 182
  • [6] Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial
    Samsky, Marc D.
    Mentz, Robert J.
    Stebbins, Amanda
    Lokhnygina, Yuliya
    Aday, Aaron W.
    Pagidipati, Neha J.
    Jones, W. Schuyler
    Katona, Brian G.
    Patel, Manesh R.
    Holman, Rury R.
    Hernandez, Adrian F.
    Gutierrez, Jorge Antonio
    ATHEROSCLEROSIS, 2021, 338 : 1 - 6
  • [7] Hepatic inflammation and fibrosis biomarkers are associated with cardiovascular risk factors but not cardiovascular disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study
    Morling, J. R.
    Williamson, R. M.
    Robertson, C. M.
    Guha, I. N.
    Fallowfield, J. A.
    Strachan, M. W. J.
    Price, J. F.
    LANCET, 2013, 381 : 79 - 79
  • [8] Prevalence of cardiovascular disease risk factors and their rates of control in Saudi patients with type 2 diabetes
    Eledrisi, Mohsen S.
    Alhaj, Buthina A.
    Rehmani, Rifat R.
    DIABETES, 2006, 55 : A534 - A534
  • [9] No Increased Risk of Cardiovascular Events with Dapagliflozin in Elderly Patients with Type 2 Diabetes Mellitus, Cardiovascular Disease, and Hypertension
    Gause-Nilsson, Ingrid Ami
    Sonesson, Christian
    Johansson, Peter A.
    Sugg, Jennifer E.
    Johnsson, Eva
    DIABETES, 2015, 64 : A4 - A4
  • [10] No increased risk of cardiovascular events with dapagliflozin in elderly patients with type 2 diabetes mellitus, cardiovascular disease and hypertension
    Gause-Nilsson, I.
    Sonesson, C.
    Johansson, P. A.
    Johnsson, E.
    DIABETOLOGIA, 2015, 58 : S362 - S363